AbbVie reports lymphoma trial success: AbbVie stock gains 2.25 percent

Published on 10/07/2026 at 15:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie cut lymphoma risk 51.00 percent in Phase 3. AbbVie stock costs EUR 241.15 on October 7, 2026 versus EUR 235.85, plus 2.25 percent.

Flatlay-Produktfoto mit generischen Blisterpackungen, Ampullen, Pipette und abstraktem Wertpapierschein — AbbVie Inc. US00287Y1091 Flatlay generische Blisterpackungen Ampullen Pipette Aktien Zertifikat und ISIN Karte, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 241.15 at Lang & Schwarz on October 7, 2026 at 3:33 p.m. CEST, up 2.25 percent versus the EUR 235.85 prior close. On October 5, AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51.00 percent in newly diagnosed diffuse large B-cell lymphoma, according to PR Newswire.

Lymphoma data expands the pipeline

The Phase 3 EPCORE DLBCL-2 trial compared the investigational combination with R-CHOP alone. The primary result was a hazard ratio of 0.49, with a p-value below 0.0001, while the reported 51.00 percent risk reduction covered patients with International Prognostic Index scores of 2 to 5.

The result gives AbbVie a potential frontline expansion for EPKINLY, which is already used in certain relapsed or refractory blood cancers. The combination remains investigational, and PR Newswire said the companies will engage global regulators on next steps.

Guidance adds an earnings counterweight

AbbVie lowered adjusted earnings-per-share guidance for the third quarter of 2026 to USD 3.73-3.77, below the USD 3.85 consensus cited by MarketBeat on October 6, 2026. The update included USD 216.0 million in acquired in-process research and development and milestone expenses.

The company also reduced full-year adjusted earnings-per-share guidance to USD 13.76-13.96 from USD 13.87-14.07, according to MarketBeat. That lower outlook contrasts with the pipeline update, leaving regulatory progress and upcoming results as separate tests for the growth story.

Analyst target rises to USD 320.00

Scotiabank raised its AbbVie price target from USD 280.00 to USD 320.00 and maintained a sector outperform rating in a report dated October 6, 2026, as reported by MarketBeat. The target change supplies a clear comparison, but it is denominated in USD and therefore is not combined with the euro quote from Lang & Schwarz.

AbbVie is scheduled to announce its third-quarter 2026 results before the market opens on October 30, 2026, according to StockTitan. The report will show whether the reduced adjusted earnings outlook and the new oncology opportunity are moving in the same direction.

AbbVie stock holds a fresh market signal

AbbVie was trading at EUR 241.15 at Lang & Schwarz on October 7, 2026 at 3:33 p.m. CEST, plus 2.25 percent versus the EUR 235.85 prior close. The move followed a 51.00 percent trial risk reduction, a lower adjusted earnings outlook and a USD 320.00 analyst target, giving investors three distinct figures to track before the October 30 report. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.